文献速递中枢神经肿瘤放疗放疗物理与技术

用于胶质母细胞瘤的PRIDE试验(NOA-28;ARO-2022-12)中提出的等毒性剂量递增放射治疗概念的剂量学可行性分析与展示

Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12).
PubMed 文献 · Clin Transl Radiat Oncol · 2023-12-03

PRIDE试验(NOA-28;ARO-2022-12;NCT05871021)计划于2023年10月开始招募,旨在通过等毒性剂量递增至75 Gy/30次并联合保护性贝伐珠单抗(BEV)来提高MGMT启动子未甲基化胶质母细胞瘤患者的中位总生存期(OS)。本研究对10例胶质母细胞瘤患者进行剂量学分析,比较参考计划与实验计划的有症状放射性坏死(RN)正常组织并发症概率(NTCP),结果显示实验计划NTCP中位数为参考计划的1.77倍,对数比较RN风险增加中位2.00倍,但危及器官约束可行;考虑BEV可能将RN风险降低约两倍后,等毒性似乎可行。

要点

  • PRIDE试验计划于2023年10月开始招募,纳入MGMT启动子未甲基化胶质母细胞瘤患者。
  • 实验计划将剂量递增至75 Gy/30次,并联合保护性贝伐珠单抗以抵消放射性坏死风险。
  • 10例患者剂量学分析显示实验计划NTCP中位数为参考计划的1.77倍,RN风险对数比较增加中位2.00倍。

核心结论

  • 考虑BEV可能将RN风险降低约两倍(作者假设),所提出的剂量递增实验计划达到等毒性似乎是可行的。

研究设计与样本

  • 剂量学可行性分析,共纳入10例诊断为胶质母细胞瘤的患者。
  • 参考计划靶区勾画遵循ESTRO-EANO 2023指南,实验计划增加整合推量体积并将60 Gy体积 margin 从1.5 cm缩小至1.0 cm。
  • 计算并比较参考计划与实验计划的有症状RN的正常组织并发症概率(NTCP)。

主要发现

  • 参考计划NTCP中位数为0.24(范围0.11-0.29),实验计划NTCP中位数为0.42(范围0.18-0.54)。
  • 实验计划NTCP中位数为参考计划的1.77倍(范围1.60-1.99)。
  • 对数比较中,RN风险增加中位2.00倍(范围1.66-2.35)。
  • 危及器官的既定约束均可行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The PRIDE trial (NOA-28; ARO-2022-12; NCT05871021) is scheduled to start recruitment in October 2023. Its primary objective is to enhance median overall survival (OS), compared to historical median OS rates, in patients with methylguanine methlyltransferase (MGMT) promotor unmethylated glioblastoma by incorporating isotoxic dose escalation to 75 Gy in 30 fractions. To achieve isotoxicity and counteract the elevated risk of radiation necrosis (RN) associated with dose-escalated regimens, the addition of protective concurrent bevacizumab (BEV) serves as an innovative approach. The current study aims to assess the dosimetric feasibility of the proposed concept. MATERIALS AND METHODS: A total of ten patients diagnosed with glioblastoma were included in this dosimetric analysis. Delineation of target volumes for the reference plans adhered to the ESTRO-EANO 2023 guideline. The experimental plans included an additional volume for the integrated boost. Additionally, the 60 Gy-volume was reduced by using a margin of 1.0 cm instead of 1.5 cm. To assess the risk of symptomatic RN, the Normal Tissue Complication Probability (NTCP) was calculated and compared between the reference and experimental plans. RESULTS: Median NTCP of the reference plan (NTCPref) and of the experimental plan (NTCPex) were 0.24 (range 0.11-0.29) and 0.42 (range 0.18-0.54), respectively. NTCPex was a median of 1.77 (range 1.60-1.99) times as high as the NTXPref. In a logarithmic comparison, the risk of RN is enhanced by a factor of median 2.00 (range 1.66-2.35). The defined constraints for the organs at risk were feasible. CONCLUSION: When considering the potential protective effect of BEV, which we hypothesized might reduce the risk of RN by approximately two-fold, achieving isotoxicity with the proposed dose-escalated experimental plan for the PRIDE trial seems feasible.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bodensohn R, Fleischmann DF, Maier SH, et al. Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12). Clin Transl Radiat Oncol. 2023. PMID: 38116137. doi:10.1016/j.ctro.2023.100706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。